Investigating the effect of injectable Acetaminophen in the treatment of Patent Ductus Arteriosus (PDA).

A comparative study of the effectiveness of injectable Acetaminophen in closing Patent Ductus Arteriosus (PDA) in Term and Preterm Neonates.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230219057459N1

Enrollment

Registered

2023-06-24

Start date

2020-03-20

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal Patent Ductus Arteriosus. Patent ductus arteriosus

Interventions

Intervention 1: The intervention group: included the use of injectable acetaminophen by Amin company with a dose of 20 mg based on weight, in the first hour and 10 mg based on weight, for every six ho

Eligibility

Sex/Gender

All

Age

3 Days to 28 Days

Inclusion criteria

Inclusion criteria: All hospitalized neonates with Patent Ductus Arteriosus(PDA) All term neonates with a gestational age of 37 weeks and more The minimum age is 3 days and the maximum age is 28 days.

Exclusion criteria

Exclusion criteria: Congenital Heart Disease Multiple Congenital Anomalies Life Threatening Disease Asphyxia Lack of parental consent

Design outcomes

Primary

Measure	Time frame
Closure of patent ductus arteriosus in neonates. Timepoint: Opening of the ductus arteriosus: before the start of the study and on the third day and the sixth day after receiving injectable acetaminophen. Method of measurement: Eco cardiography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Mehdi Bagheri

Kerman University of Medical Sciences

mehdi_b_ped@yahoo.com0098343138000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026